These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26466044)

  • 1. EXAMINE: targeting risk and treatment in diabetes - Authors' reply.
    White WB; Kupfer S; Zannad F
    Lancet; 2015 Oct; 386(10002):1445. PubMed ID: 26466044
    [No Abstract]   [Full Text] [Related]  

  • 2. EXAMINE: targeting risk and treatment in diabetes.
    Derosa G; Maffioli P
    Lancet; 2015 Oct; 386(10002):1443. PubMed ID: 26466042
    [No Abstract]   [Full Text] [Related]  

  • 3. EXAMINE: targeting risk and treatment in diabetes.
    Hülsmann M; Pacher R; Neuhold S
    Lancet; 2015 Oct; 386(10002):1444-5. PubMed ID: 26466043
    [No Abstract]   [Full Text] [Related]  

  • 4. EXAMINE: targeting risk and treatment in diabetes.
    Riche DM; Davis C
    Lancet; 2015 Oct; 386(10002):1443-4. PubMed ID: 26466041
    [No Abstract]   [Full Text] [Related]  

  • 5. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
    Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB;
    Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intensive glycaemic control on ischaemic heart disease - Authors' reply.
    Gerstein HC; Miller ME
    Lancet; 2015 Mar; 385(9974):1180-1. PubMed ID: 25845790
    [No Abstract]   [Full Text] [Related]  

  • 7. Lessons from SAVOR and EXAMINE: some important answers, but many open questions.
    Schernthaner G; Sattar N
    J Diabetes Complications; 2014; 28(4):430-3. PubMed ID: 24713467
    [No Abstract]   [Full Text] [Related]  

  • 8. Welcome reassurance about GLP-1 drugs--but they are still young and not fully grown.
    Riddle MC
    Diabetes Care; 2015 Feb; 38(2):183-5. PubMed ID: 25614687
    [No Abstract]   [Full Text] [Related]  

  • 9. Alogliptin (nesina) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May; 55(1417):41-3. PubMed ID: 23715128
    [No Abstract]   [Full Text] [Related]  

  • 10. New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive.
    Mitka M
    JAMA; 2013 Oct; 310(14):1435-6. PubMed ID: 24104360
    [No Abstract]   [Full Text] [Related]  

  • 11. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Derosa G; Maffioli P
    N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study.
    Eurich DT; Weir DL; Simpson SH; Senthilselvan A; McAlister FA
    Diabet Med; 2016 May; 33(5):621-30. PubMed ID: 26206341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intensive glycaemic control on ischaemic heart disease.
    Tsujimoto T; Yamamoto-Honda R
    Lancet; 2015 Mar; 385(9974):1180. PubMed ID: 25845791
    [No Abstract]   [Full Text] [Related]  

  • 14. Glycaemic control, cardiovascular disease, and mortality in type 2 diabetes.
    Chiasson JL; Le Lorier J
    Lancet; 2014 Nov; 384(9958):1906-7. PubMed ID: 25088436
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
    Jermendy G
    Orv Hetil; 2016 Apr; 157(16):603-10. PubMed ID: 27063427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.
    Shimada YJ; Cannon CP; Liu Y; Wilson C; Kupfer S; Menon V; Cushman WC; Mehta CR; Bakris GL; Zannad F; White WB;
    Am Heart J; 2016 May; 175():18-27. PubMed ID: 27179720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
    Cavender MA; White WB; Jarolim P; Bakris GL; Cushman WC; Kupfer S; Gao Q; Mehta CR; Zannad F; Cannon CP; Morrow DA
    Circulation; 2017 May; 135(20):1911-1921. PubMed ID: 28246236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
    Huang Y; Abdelmoneim AS; Light P; Qiu W; Simpson SH
    J Diabetes Complications; 2015 Mar; 29(2):196-202. PubMed ID: 25534984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
    White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
    Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?
    Nagendran J; Oudit GY; Bakal JA; Light PE; Dyck JR; McAlister FA
    Diabetes Obes Metab; 2013 Nov; 15(11):1022-8. PubMed ID: 23668425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.